Treatment of obesity and obesity-related disorders
US-2024277813-A1 · Aug 22, 2024 · US
Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695) · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C07K14/575 |
| Official title | Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695) |
| Display label | Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695) |
| Total patents | 776 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is declining.
| Year | Patents |
|---|---|
| 2015 | 76 |
| 2016 | 63 |
| 2017 | 84 |
| 2018 | 59 |
| 2019 | 89 |
| 2020 | 75 |
| 2021 | 70 |
| 2022 | 78 |
| 2023 | 55 |
| 2024 | 59 |
| 2025 | 56 |
| 2026 | 12 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Aquaretic and natriuretic polypeptides lacking vasodilatory activity
US-2015376255-A1 · Dec 31, 2015 · US
Protein therapy for treatment of retinal diseases
US-2015374791-A1 · Dec 31, 2015 · US
Kiss1r receptor agonist compounds and use thereof for inducing ovulation in mammals
US-2015361138-A1 · Dec 17, 2015 · US
Methods and Pharmaceutical Composition for the Preservation of Vascular Endothelial Cell Barrier Integrity
US-2015353618-A1 · Dec 10, 2015 · US
Compositions of Active WNT Protein
US-2015344846-A1 · Dec 3, 2015 · US
Methods of treating diabetes using therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptides
US-9200083-B2 · Dec 1, 2015 · US
Insulinotropic peptide derivative with modified n-terminal charge
US-2015329611-A1 · Nov 19, 2015 · US
Exendin-4 derivatives as peptidic dual glp-1/glucagon receptor agonists
US-2015315260-A1 · Nov 5, 2015 · US
PEG modified exendin or exendin analog and compositions and use thereof
US-9175060-B2 · Nov 3, 2015 · US
Gip-glp-1 dual agonist compounds and methods
US-2015299281-A1 · Oct 22, 2015 · US
A composition for treating diabetes or diabesity comprising oxyntomodulin analog
US-2015299282-A1 · Oct 22, 2015 · US
Polypeptides, nucleic acids and uses thereof
US-2015299311-A1 · Oct 22, 2015 · US
Isolated polynucleotide that encodes an ActRIIa-Fc fusion polypeptide
US-9163075-B2 · Oct 20, 2015 · US
Therapeutic agent for amyotrophic lateral sclerosis
US-2015265680-A1 · Sep 24, 2015 · US
Compositions of active Wnt protein
US-9139636-B2 · Sep 22, 2015 · US
Non-cytotoxic protein conjugates
US-9139635-B2 · Sep 22, 2015 · US
Ghrelin analogs
US-9133261-B2 · Sep 15, 2015 · US
Therapeutic agents comprising insulin and elastin-like peptides
US-9127047-B2 · Sep 8, 2015 · US
Method of treatment of cardiovascular or renal conditions with natriuretic polypeptides with unique pharmacologic profiles
US-9115209-B2 · Aug 25, 2015 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C07K14/575?
- CPC C07K14/575 is the Cooperative Patent Classification code for “Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695).”
- How many patents are filed under CPC C07K14/575 (Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695))?
- Our database includes 776 publications tagged with this CPC code.
- Is patent activity under CPC C07K14/575 growing?
- Publication counts under this code: 59 in 2024 vs 56 in 2025 (latest complete years).